StockData

iBio vs MediciNova

IBIO and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IBIO and MNOV compare

MediciNova is the larger company, worth 1.4 times as much as iBio ($66.0M against $48.1M).

MediciNova keeps more of each dollar of sales as profit, with a net margin of −1168% compared with −3244% at iBio.

iBio scores higher on the StockData Score (9 against 7 for MediciNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIBIOMNOV
Size and price
Market cap$48.1M$66.0M
Share price$0.748$1.34
Change, 1 year−35.5%−13.5%
Change, 5 years−99.8%−58.4%
Beta (5Y)1.66−0.00
Employees236
StockData Score
Total score9 (better)7
Valuation score11
Growth score1 (better)0
Performance score2 (better)1
Health score55
Dividend score00
Valuation
P/S44.8× (better)71.7×
P/B0.6× (better)1.8×
FCF yield−57.3%−13.8% (better)
Growth
Revenue growth (TTM)115%–
Revenue growth, 5Y average−46.9%–
Profitability
Operating margin−3491%−1287% (better)
Net margin−3244%−1168% (better)
FCF margin−2566%−991% (better)
Return on equity−51.8%−25.6% (better)
Return on invested capital−728%−76.6% (better)
Financial health
Debt / equity0.000.00
Current ratio9.48 (better)8.75
Altman Z-score−3.43−3.11 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions54.0%10.5%
Held by insiders0.47%12.8%
Insider net buying, 12 months$98.1K (better)−$1.7M
Short interest, % of float6.3%0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.